Physician profile
John P Imm
NPI 1215939848
$3,312.27
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $497 · 2021: $320 · 2022: $320 · 2023: $715 · 2024: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $787.56 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $394.87 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $339.05 | 2021-2024 | |
| Pfizer INC. | $336.26 | 2019-2024 | |
| Lilly USA, LLC | $160.86 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $129.65 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $109.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.03 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $103.74 | 2019-2021 | |
| Exact Sciences Corporation | $100.54 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $80.50 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.90 | 2019-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $60.76 | 2023-2024 | Auvelity, Sunosi |
| Amgen INC. | $55.74 | 2019-2024 | Prolia, Evenity |
| Biohaven Pharmaceuticals, INC. | $45.75 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.75 | 2022-2023 | |
| Dexcom, INC. | $42.82 | 2024 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $36.34 | 2023-2024 | Uptravi, Opsumit |
| Lundbeck LLC | $35.70 | 2023-2024 | Rexulti |
| Phadia US INC. | $31.65 | 2020-2023 | Immunocap |
| Dynavax Technologies Corporation | $29.35 | 2024 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $28.05 | 2019-2022 | |
| Almatica Pharma LLC | $25.88 | 2022 | |
| Smith+Nephew, INC. | $24.31 | 2019 | |
| Horizon Therapeutics Plc | $20.29 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.02 | 2022 | |
| Shield Therapeutics INC | $17.82 | 2023 | Accrufer |
| Ucb, INC. | $15.43 | 2023 | |
| Allergan, INC. | $14.80 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.26 | 2022 | |
| Eisai INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Imm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.